FDA Approves Eli Lilly's Omvoh as First-in-Class Treatment for Ulcerative Colitis
The FDA has approved Eli Lilly's new drug, Omvoh, for the treatment of ulcerative colitis. Omvoh is an antibody that blocks IL-23p19, a molecule involved in sustaining the disease. Clinical trials showed significant improvement in symptoms for patients taking Omvoh compared to a placebo, with minimal side effects. The drug's list price is $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin, but patients with commercial insurance may pay as little as $5 per month for up to 30 months.